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 SUMMARY 
The Q-SNARE STX19 is S-acylated by Golgi localised S-acyltransferases and this lipidation 
targets the protein to MICAL-L1-positive tubular recycling endosomes and also protects it 
from proteasomal degradation.  
 
ABSTRACT 
STX19 is an unusual Qa-SNARE as it lacks a C-terminal transmembrane domain. However, it 
is efficiently targeted to post-Golgi membranes. We have set out to determine the 
intracellular localisation of endogenous STX19 and elucidate the mechanism by which it is 
targeted to membranes. We have found that a pool of STX19 is localised to tubular recycling 
endosomes where it co-localises with MICAL-L1 and Rab8. Using a combination of genetic, 
biochemical and cell based approaches we have identified that STX19 is S-acylated at its C-
terminus and is a substrate for several Golgi localised S-acyltransferases, suggesting that 
STX19 is initially S-acylated at the Golgi before trafficking to the plasma membrane and 
endosomes. Surprisingly, we have found that S-acylation is a key determinant in targeting 
STX19 to tubular recycling endosomes, suggesting that S-acylation may play a general role in 
directing proteins to this compartment. In addition, S-acylation also protects STX19 from 
proteosomal degradation indicating that S-acylation regulates the function of STX19 at 
multiple levels. 
 
INTRODUCTION 
Over the past 30 years, the majority of the molecular machinery required for intracellular 
protein transport has been identified and functionally characterised. However, our 
understanding of how this machinery is regulated by post-translational modifications is less 
clear. This is especially true for lipid-based modifications which are generally more difficult 
to study. It is estimated that up to 10% of the human proteome may be S-acylated (Blanc et 
al., 2015) and the number of confirmed S-acylated proteins is increasing rapidly due to 
proteomic based approaches (Collins et al., 2017; Martin and Cravatt, 2009; Martin et al., 
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2011). However, for the majority of these proteins, it is unclear what role S-acylation plays 
in regulating their function. S-acylation is a reversible post-translational modification of free 
cysteine residues with fatty acids, predominantly palmitic acid (Smotrys and Linder, 2004); 
hence the process is also referred to as palmitoylation. However, other fatty acids with 
different chain lengths and unsaturation can also be added to S-acylated proteins (Muszbek 
et al., 1999). S-acylation not only targets peripheral proteins to membranes but also 
regulates protein trafficking, turnover and cell signalling (Akimzhanov and Boehning, 2015; 
Linder and Deschenes, 2007; Misaki et al., 2010; Schmick et al., 2014). 
S-acylation, in humans, is catalysed by a family of 23 S-acyltransferases (Fukata et al., 2004). 
These enzymes are multi-spanning transmembrane proteins that are localised to a broad 
range of intracellular membranes including the ER, Golgi, and plasma membrane (Greaves 
and Chamberlain, 2011a; Ohno et al., 2006).  All S-acyltransferases (also known as zDHHC 
enzymes) have a highly conserved zinc finger like domain that contains the amino acid 
sequence DHHC (Asp-His-His-Cys) which is essential for their activity.  On the whole, it is not 
well understood how these enzymes recognise their substrates, so the extent of substrate 
specificity remains unclear. S-acylation is the only lipid-based modification that is reversible 
and there are several examples where a cycle of S-acylation and de-S-acylation is critical for 
regulating trafficking and signalling (Akimzhanov and Boehning, 2015; Schmick et al., 2014). 
Two serine hydrolases, APT1 and APT2 were initially thought to be the only enzymes that 
catalyse de-S-acylation in the cytoplasm (Duncan and Gilman, 1998; Tomatis et al., 2010). 
However, there is increasing evidence there may be many more serine hydrolases involved 
in this process (Lin and Conibear, 2015; Martin et al., 2011; Yokoi et al., 2016).  
Intracellular membrane fusion is driven by a family of evolutionarily conserved proteins 
known as SNAREs (Jahn and Scheller, 2006). The majority of SNAREs (32 out of 38) have a 
transmembrane domain at their C-termini which, targets them to membranes (Bock et al., 
2001; Kloepper et al., 2007). However, there are several SNAREs that lack a membrane-
spanning sequence. These include the R-SNARE, Ykt6; the Qa-SNAREs, syntaxin 11 (STX11) 
and syntaxin 19 (STX19); the Qbc-SNAREs SNAP23, 25, 29 and 47. Most of these SNAREs are 
targeted to membranes via the post-translational lipidation of conserved cysteine residues. 
For example, Ykt6 is both farnesylated and S-acylated (Fukasawa et al., 2004). SNAP23 and 
SNAP25 are S-acylated at a cysteine-rich domain located just downstream of the first SNARE 
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motif (Greaves et al., 2010) and STX11 is S-acylated at its C-terminus (Hellewell et al., 2014). 
There is significant evidence that the lipidation of these SNAREs not only regulates their 
membrane targeting but also regulates their trafficking and function. For example, S-
acylation of Ykt6 at cysteine 194 leads to a conformational switch that exposes the SNARE 
motif and makes it accessible for interaction with other SNAREs (Fukasawa et al., 2004; 
Gordon et al., 2017; Wen et al., 2010). Altering the levels of SNAP25 S-acylation by mutating 
key cysteine residues changes its localisation suggesting that S-acylation can regulate 
SNAP25 trafficking (Greaves and Chamberlain, 2011b). S-acylation is also required for the 
correct targeting of STX11 to the immune synapse (Hellewell et al., 2014), where STX11 is 
thought to play a role in the regulation of lytic granule fusion with the plasma membrane 
(D'Orlando et al., 2013). Loss of STX11 function in humans causes the immunoproliferative 
disorder FHL4 (zur Stadt et al., 2005). Several mutations that cause this disorder result in the 
truncation of the cysteine-rich domain of STX11 (Hellewell et al., 2014), highlighting the 
importance of S-acylation for STX11 function.  
STX19 is a close homologue of STX11 (38% amino acid identity) (Wang et al., 2006) and has 
been identified as an S-acylated protein in a global proteomics screen (Kang et al., 2008). 
However, it is unclear which residues in STX19 are S-acylated and what role S-acylation has 
in regulating STX19 trafficking and function. Like STX11, STX19 has a restricted tissue 
distribution and its mRNA is predominantly detected in mucosal epithelium of the gut and 
the skin (Wang et al., 2006). Work from our group and others have shown that depletion of 
STX19 using siRNA perturbs the constitutive secretion of both soluble and transmembrane 
anchored cargo (Gordon et al., 2010) (Simpson et al., 2012). Immunoprecipitation studies 
have found that STX19 interacts with post-Golgi SNAREs thought to be involved in fusion 
with the cell surface, suggesting that STX19 may be a novel plasma membrane localised Q-
SNARE involved in biosynthetic transport (Gordon et al., 2010).  
In this study, we sought to gain an insight into the function of STX19 by elucidating where 
STX19 is localised within the cell and determining how S-acylation regulates its trafficking. 
We have found that the highly conserved cysteine-rich domain of STX19 
(KKRNPCRVLCCWCCPCCSSK) is S-acylated at several cysteines and is necessary and sufficient 
for targeting STX19 to tubular recycling endosomes and the plasma membrane. Blocking S-
acylation by either treating cells with the 2-bromopalmitate or mutating cysteine residues in 
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the cysteine-rich domain alters the steady-state localisation of STX19. In addition, these 
perturbations reduce expression levels of STX19 suggesting that S-acylation regulates STX19 
stability. The S-acylation of STX19 can be catalysed by several Golgi localised zDHHCs 
suggesting that STX19 is first S-acylated at the Golgi and subsequently traffics to the cell 
surface and tubular recycling endosomes. Over expression of GFP tagged STX19 perturbs the 
trafficking of Rab8 suggesting that STX19 may be involved in the fusion of Rab8 positive 
vesicles with the plasma membrane.  
 
EXPERIMENTAL PROCEDURES 
Antibodies and Reagents 
The polyclonal antibody against STX19 was generated by immunising rabbits with GST-
STX191-100. The antiserum was affinity purified as in (Page and Robinson, 1995) and diluted 
1/200 for microscopy. An anti-HA mouse monoclonal antibody (16B12) was purchased from 
BioLegend (Cat No 901503; 1/200 microscopy and 1/1000 blotting). A rabbit polyclonal and 
monoclonal antibody to Rab8A were purchased from ProteinTech (Cat No 55296-1-AP; 
1/200 microscopy) and Cell Signalling Technology, respectively (Cat No Rabbit mAb #6975; 
1/500 for microscopy). The rabbit polyclonal antibody against GFP (1/200 microscopy and 
1/1000 blotting) was previously described (Gordon et al., 2017). The Alexa-488 and 594 
conjugated secondary antibodies for fluorescence microscopy were purchased from 
ThermoFisher and used at 1/1000. The HRP conjugated secondary antibodies for 
immunoblotting were purchased from Jackson ImmunoResearch Laboratories and used at 
1/5000. For click chemistry analysis, mouse anti-GFP antibody (JL8) was obtained from 
TaKaRa Clontech (Cat No 632381, 1/1000 blotting); rat anti-HA antibody (3F10) was 
purchased from Sigma (Cat No 000000011867423001, 1/1000 blotting) and the IR dye 
conjugated secondary antibodies were purchased from LI-COR. All restriction enzymes were 
purchased from New England Biolabs. All primers were purchased from SigmaAldrich. GFP-
Trap beads were purchased from Chromotek (Cat No gta-20). 
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 Expression constructs 
Human STX19 (Gene ID: 415117) was used as the template for all the constructs used in this 
study. Wild-type and mutant HA-STX19 expression constructs were generated by PCR and 
cloned into pIRES-NEO (GenBank Accession number: U89673). GFP-STX19 expression 
constructs (GFP-STX191-294 and GFP-STX191-277) were generated by PCR and cloned into 
pEGFP-C1 (GenBank Accession number: U55763). The GFP-cysteine-rich domain construct 
(GFP-STX19275-294) was generated by annealing oligos and ligating them into pEGFP-C3 
(GenBank Accession number: U57607). FKBP-STX191-294 and FKBP-STX191-277 were generated 
by PCR and cloned into pIRES-NEO. The HA tagged zDHHC expression library was a kind gift 
from M. Fukata (17). The pCAG-mGFP (GFP fused with GAP43 S-acylation sequence) was 
obtained from Addgene (14757) (Matsuda and Cepko, 2007). The GFP-HRAS construct was a 
kind gift from I. Prior (University of Liverpool). The MitoTRAP (pMito-mCherry-FRB) and GFP-
FKBP constructs were a generous gift from S. Royle (Cheeseman et al., 2013). All constructs 
ǁĞƌĞƐĞƋƵĞŶĐĞĚƵƐŝŶŐƚŚĞhŶŝǀĞƌƐŝƚǇŽĨ^ŚĞĨĨŝĞůĚ ?ƐŽƌĞ'ĞŶŽŵŝĐ&ĂĐility.  
 
Cell culture and transfections 
HeLaM cells were originally obtained from the laboratory of M.S Robinson (University of 
Cambridge) and HEK-293T (CRL-3216) cells were obtained from ATCC. Both cell lines were 
routinely tested for mycoplasma contamination. HeLaM and HEK-293T cells were grown in 
DMEM supplemented with 10% fetal bovine serum (Life technologies), 100 IU/mL penicillin, 
 ? ? ? ʅŐ ?ŵ> ƐƚƌĞƉƚŽŵǇĐŝŶ ĂŶĚ  ? ŵD ŐůƵƚĂŵŝŶĞ  ?^ŝŐŵĂ-Aldrich) at 37°C in a 5% CO2 
humidified incubator. In some instances, HeLaM cells were treated with either 5 µM MG132 
(Cayman Chemical, USA) or 100 µM 2-bromopalmitate (Sigma-Aldrich). HeLaM and HEK-293 
cells were transfected using PEI (ratio 1 part DNA to 5 parts PEI). Cells were analysed 24-48 
hours post-transfection. siRNA transfections were performed as in Gordon et al., 2010. 
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 Immunofluorescence microscopy 
Approximately, 2x105 HeLaM cells were seeded onto glass coverslips and grown overnight. 
The cells were rapidly fixed, by adding an equal volume of room temperature (RT) 4% 
paraformaldehyde in PBS to the culture media, as soon as the cells were removed from the 
incubator. After one minute, the fixative was removed and replaced with fresh fixative. The 
cells were incubated for a further 15 minutes at RT. The fixative was removed and the cells 
washed three times with PBS. The cells were incubated for 5 minutes with 0.1 M glycine in 
PBS. The cells were permeabilised using 0.1% saponin in PBS containing 5% FCS. The cells 
were stained with the appropriate primary and secondary antibodies for one hour at RT. The 
coverslips were mounted onto microscope slides using ProLong Gold antifade reagent 
(ThermoFisher) and observed with a 60X oil immersion objective (Olympus BX61 motorised 
wide field epifluorescence microscope). Images were captured using a Hamamatsu Orca 
monochrome camera and processed using ImageJ.  
 
Immunoprecipitation acyl-release assay  
Cells expressing GFP-STX19275-294 were harvested 48 hours post-transfection by scraping and 
centrifugation (1000 rpm for 5 minutes at 4°C). The cell pellets were resuspended in 1 mL of 
RIPA lysis buffer, (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% NP-40, 0.5% 
Sodium deoxycholate, 0.1% SDS, and protease inhibitors) and passed through a 
QIAShredder (Qiagen). The samples were then incubated for one hour at 4°C to ensure 
complete solubilisation. Insoluble material was removed by centrifugation at 13,000 rpm for 
15 minutes at 4°C. The supernatant was then incubated with GFP-Trap beads for 3 hours at 
4°C (Rothbauer et al., 2008).  The beads were washed three times with RIPA buffer and two 
times with Tris buffered saline. The immunoisolated protein was then reduced and alkylated 
using 5 mM TCEP and 50 mM iodoacetamide in 50 mM Tris (pH 8). The beads were then 
washed five times with 50 mM Tris (pH 7.5).  The beads were then divided in to two 
samples. Sample (a) was incubated with 1 M hydroxylamine in 50 mM Tris (pH 7.5), to 
cleave thioester bonds and sample (b) was incubated with 50 mM Tris (pH 7.5) as a control. 
The beads were washed three times with 50 mM Tris (pH 7.5). The protein was eluted from 
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the beads using 8 M Guanidine-HCl at 95 oC for 10 minutes.  The eluted protein was 
digested for 4 hours at 37 oC with 0.5 µg of trypsin prepared in 100 mM ammonium 
bicarbonate solution (pH 8). The peptides were dried overnight using a vacuum 
concentrator. Peptides were resuspended in 0.5 % formic acid for 10 minutes at RT with 
agitation.  
 
Mass spectrometry analysis 
Peptides were analysed by nanoLC-MS/MS on an Orbitrap Elite (ThermoFisher) hybrid mass 
spectrometer equipped with a nanospray source, coupled with an Ultimate RSLCnano LC 
System (Dionex). The system was controlled by Xcalibur 2.1 (ThermoFisher) and DCMSLink 
2.08 (Dionex). Peptides were desalted on-line using a micro-Precolumn cartridge (C18 
Pepmap 100, LC Packings) and then separated using a 60 min RP gradient (4-32% 
acetonitrile/0.1% formic acid) on an EASY-Spray column, 15 cm x 50 µm ID, PepMap C18, 2 
µm particles, 100 Å pore size (Thermo). The mass spectrometer was operated with a cycle of 
one MS (in the Orbitrap) acquired at a resolution of 60,000 at m/z 400, with the top 20 most 
abundant multiply-charged (2+ and higher) ions in a given chromatographic window 
subjected to CID fragmentation in the linear ion trap. An FTMS target values of 1e6 and an 
ion trap MSn target value of 1e4 was used and with the lock mass (445.120025) enabled. 
Maximum FTMS scan accumulation time of 500ms and maximum ion trap MSn scan 
accumulation time of 100ms were used. Dynamic exclusion was enabled with a repeat 
duration of 45s with an exclusion list of 500 and exclusion duration of 30s. MS data was 
analysed using MaxQuant (Cox and Mann, 2008) version 1.5.5.1. Data were searched against 
human UniProt sequence databases (downloaded June 2015) using the following search 
parameters: trypsin with a maximum of 2 missed cleavages, 7 ppm for MS mass tolerance, 
0.5 Da for MS/MS mass tolerance, with Acetyl (Protein N-term) and Oxidation (M) set as 
variable modifications and carbamidomethyl (C) as a fixed modification. Previously S-
acylated sites were identified by the lack of carbamidomethyl (C) (-57.0214) which was set 
as a variable modification. A maximum of 6 modifications per peptide was allowed. A 
protein FDR of 0.01 and a peptide FDR of 0.01 was used for identification level cut offs. 
Label free quantification of peptides +/- hydroxylamine treatment was performed using 
MaxQuant calculated peptide intensities. S-acylation site occupancies were calculated by 
expressing peptide intensities of modified peptides to their unmodified counterparts. 
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 Immunoblotting 
Cells were washed three times with ice-cold PBS and lysed with SDS sample buffer 
ĐŽŶƚĂŝŶŝŶŐ  ?й ɴ-mercaptoethanol. The cell lysates were passed through a QIAShredder 
(Qiagen) three times to sheer chromosomal DNA. The lysates were boiled at 100°C for 10 
minutes. The samples were then separated using SDS-PAGE and transferred overnight onto 
a 0.45 µm PVDF membrane (GE Healthcare Life Sciences). The membranes were blocked in 
PBS containing 5% milk powder and 1% Tween-20 at RT for 30 minutes. The membranes 
were probed with specific antibodies diluted in the blocking buffer. The probed membranes 
were washed thoroughly with PBS and the damp membranes incubated with 
Clarity ECL Western blot Substrate for 5 minutes at RT. The excess substrate was removed 
and the signal detected using either X-ray film (Fujifilm) or a LiCOR c-DiGiT. Quantification of 
the immunoblots was performed using Image Studio Lite Ver 4.0 (Li-COR Inc.). 
 
17-octadecynoic acid labelling coupled to click chemistry 
The 17-octadecynoic acid labelling coupled to click chemistry was performed as described in 
(Martin and Cravatt, 2009; Yap et al., 2010) with some minor modifications. HEK-293T cells 
were seeded onto 24-well plates, grown overnight and co-transfected with 23 HA-tagged S-
acyltransferases and GFP-STX191-294 or GFP-STX19275-294 (0.8ʅg of STX19 construct to 1.6ʅg 
of HA-zDHHC). 24 hours post-transfection, the cells were serum-starved in DMEM 
containing 1 mg/ml fatty-acid free BSA for 30 minutes at 37°C. The cells were then labelled 
for 3 hours at 37oC with 100 µM 17-octadecynoic acid. The cells were washed two times 
with ice-cold PBS and then lysed on ice in 50 mM Tris (pH8.0) containing 0.5% SDS and 
protease inhibitors. The cell lysates were then incubated with the click reaction buffer (final 
concentration; 2.5 µM IR-800 dye, 2 mM CuSO4, 0.2 mM TBTA and 4 mM Ascorbic Acid).  
The click reaction buffer and ascorbic acid were freshly prepared on the day of the 
experiment. The samples were vortexed and incubated for 1 hour at RT with end-over-end 
rotation. After the click reaction, the proteins were precipitated using acetone and the 
pellets allowed to air-dry for 5 minutes. The pellets were resuspended in 1XSDS sample 
buffer containing 25mM DTT and heated at 95oC for 5 minutes. The samples were separated 
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by SDS-PAGE (12%) and transferred on to nitrocellulose membranes and probed with 
antibodies against GFP and HA. 
 
Statistical analysis 
All bar graphs presented in this manuscript were prepared using GraphPad Prism (GraphPad 
Software). For each experiment, a minimum of three biological repeats were performed. In 
all graphs the error bars show the mean ± standard error mean. An unpaired t-test was 
performed using GraphPad Prism to calculate P values.   
 
RESULTS 
A pool of STX19 is localised to the plasma membrane and tubular recycling endosomes 
To gain insight into the localisation of STX19 and its potential function we have transiently 
transfected HA-tagged STX19 into HeLaM cells (Fig. 1A). As previously reported, we 
observed recombinant STX19 at the plasma membrane and on intracellular membranes 
(Gordon et al., 2010; Wang et al., 2006). The intracellular labelling was very striking with 
STX19 present on branched tubular structures that were between 2-20ʅm in length, which 
emanate from the perinuclear region of the cell. A similar localisation pattern was also 
observed with a C-terminally tagged construct indicating that the position of the tag was not 
interfering with STX19 targeting (Fig. 1A). To determine if endogenous STX19 is also 
localised to branched tubular membranes we generated a rabbit polyclonal antibody to 
STX19 and performed immunostaining. Like recombinant STX19, we observed a pool of 
endogenous STX19 localised to branched tubular structures. The tubular staining is specific 
as the signal can be depleted using a previously validated siRNA targeting STX19 (Fig. 1B) 
(Gordon et al., 2010).  
Endocytic recycling machinery such as Rab8 and MICAL-L1 are localised to tubular recycling 
endosomes (Rahajeng et al., 2012; Sharma et al., 2009). These endosomes contain 
endocytosed proteins such as MHC-I and GPI anchored proteins (CD55 and CD59). Thus, we 
hypothesised that STX19 may also be localised to this compartment. To determine if this is 
the case, we performed co-localisation experiments with endogenous STX19, MICAL-L1, 
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CD55 and recombinant Rab8 (Fig. 1C). As previously reported, MICAL-L1 and Rab8 were 
found on branched tubular membranes in the majority of cells. As predicted, these 
structures co-localise with endogenous STX19. CD55 is predominantly found at the cell 
surface in HelaM cells. However, a small intracellular pool can be observed that co-localises 
with STX19. Taken together, our results indicate that a pool of endogenous STX19 is found 
on tubular recycling endosomes.  
 
The cysteine-rich domain of STX19 is required for targeting STX19 to the plasma 
membrane and tubular recycling endosomes 
STX19 is a Qa-SNARE that is predicted to have a folded Habc domain and a single SNARE 
motif. Unlike the majority of Qa ?SNAREs, STX19 lacks the standard hydrophobic stretch of 
amino acids at its C-terminus that act as a membrane anchor. However, STX19 has a highly 
conserved cysteine-rich region at its C-terminus that has previously been predicted to be 
lipid modified (Fig. 2A, Table S1) (Wang et al., 2006). The conserved region consists of an 
upstream basic patch (K/R) followed by a series of cysteine residues separated by a bulky 
hydrophobic residue (W/F) and a proline residue. To investigate the importance of the 
cysteine-rich region in STX19 trafficking we have deleted this region and determined the 
localisation of the mutant protein. In addition, we also investigated the role of the SNARE 
motif in STX19 trafficking by deleting this region. Wild-type STX19 (STX191-294) was localised 
to the plasma membrane and Rab8 positive tubules, whereas the mutant construct lacking 
the cysteine-rich domain (STX191-277) was found in the cytoplasm (Fig. 2B and quantified in 
C), see Fig. S1 for representative images showing Rab8 co-staining. In addition to the 
observed mis-localisation, we also observed a significant reduction in the levels of the 
STX191-277 construct so longer exposure times were required to obtain comparable images 
for this mutant construct (this phenotype is explored further further in Fig. 6). These results 
suggest that the cysteine-rich domain of STX19 is required for targeting the protein to the 
plasma membrane and Rab8 positive tubular recycling endosomes. Deletion of the coiled-
coil domain from STX19 (STX19ѐ218-271) did not significantly alter the localisation of STX19 
suggesting that this domain is dispensable for its correct intracellular localisation (Fig. 2B 
and quantified in C).  
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To determine if the cysteine-rich region of STX19 is preferentially targeting STX19 to tubular 
recycling endosomes, we replaced it with the transmembrane domain of the endosomal Qa-
SNARE STX13 (Prekeris et al., 2000). HeLaM cells were transfected with the hybrid construct 
(STX191-277/STX13251-276) and the localisation of the protein determined. The hybrid 
construct was effectively targeted to the plasma membrane but its association with the 
Rab8 positive tubules was significantly reduced suggesting that the cysteine-rich region 
provides trafficking information which allows STX19 to be targeted to tubular recycling 
endosomes (Fig. 2B and quantified in C). To explore this observation further, we fused the 
cysteine-rich region onto GFP. HeLaM cells were transfected with either full length STX19 
(GFP-STX191-294) or the cysteine-rich region alone (GFP-STX19275-294). Both constructs were 
found at the plasma membrane and on tubular recycling endosomes as defined by co-
localisation with Rab8 (Fig. 2D). Taken together, these results indicate that the cysteine-rich 
region of STX19 is capable of targeting proteins to tubular recycling endosomes without the 
need for any additional sorting information. Interestingly, other S-acylated proteins, such as 
RAS, are also trafficked to tubular recycling endosomes in HeLaM cells suggesting that S-
acylation may have a more general role in targeting proteins to this compartment (Fig. S2). 
 
Inhibition of S-acylation blocks the targeting of STX19 to the plasma membrane and 
tubular recycling endosomes 
Our transfection studies indicated that the cysteine-rich domain of STX19 is able to target to 
membranes independently from the rest of the protein suggesting that this is the domain 
most likely to be S-acylated. To test this hypothesis, we inhibited S-acylation in vivo using 2-
bromopalmitate (2-BP) (Resh, 2006). HeLaM cells were transfected with GFP-STX191-294 or 
GFP-STX19275-294 and treated with 100 µM 2-BP overnight and the steady state distribution 
of the expression constructs were determined using fluorescence microscopy (Fig. 3A and 
C). In the control cells, GFP-STX191-294 and GFP-STX19275-294 were localised to tubular 
recycling endosomes and the plasma membrane. However, in the cells treated with 100µM 
2-BP the constructs became predominantly cytosolic (Fig. 3A, C and quantified in B and D). 
We also observed the levels of the constructs in the 2-BP treated samples were markedly 
reduced compared to the control samples and the full-length STX19 construct (GFP-STX191-
294) was most affected. Thus, we used MG132 to inhibit the degradation of the full length 
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STX19 construct (GFP-STX191-294). This degradation phenotype is explored further in Fig. 6. 
To determine if S-acylation was also required for targeting endogenous STX19 to tubular 
recycling endosomes, we treated non-transfected cells with 100 µM 2-BP overnight and 
performed STX19 immunostaining (Fig. 3E and quantified in F). In control cells, STX19 is 
localised to tubular recycling endosomes where it co-localises with MICAL-L1. In the 2-BP 
treated cells STX19 staining is lost from tubular recycling endosomes. It is worth noting that 
this treatment also perturbs the localisation of MICAL-L1. However, a significant pool of the 
protein still remains associated with the tubular recycling endosomes although they appear 
shorter in nature. Our results suggest that S-acylation plays an important role in targeting 
both recombinant and endogenous STX19 to tubular recycling endosomes.  
 
The cysteine-rich domain of STX19 is S-acylated at several sites 
STX19 has eight cysteine residues with seven of them found in the conserved cysteine-rich 
domain at its C-terminus. To identify which of the seven cysteines are S-acylated we 
developed an immunoprecipitation acyl-release assay. GFP-STX191-294 was transfected into 
HEK-293T cells and then immuno-isolated using GFP-TRAP beads. The samples were 
reduced with TCEP (which does not affect acyl thioester bonds (Yang et al., 2010) and then 
alkylated to block all free (unmodified) cysteine residues. Samples were then treated with 
hydroxylamine at neutral pH to selectively cleave lipid-protein thioester bonds. The protein 
was then eluted from the resin and digested into peptides using trypsin. Digests were 
analysed by LC-MS/MS and S-acylated residues inferred by quantitative analysis of the 
relative levels of non-alkylated cysteine residues (i.e. protected from alkylation by S-
acylation) with and without hydroxylamine treatment. Analysis of the mass spectrometry 
data for GFP-STX191-294 identified C-terminal tryptic peptides (VLCCWCCPCCSSK) that 
showed evidence of S-acylation at several sites including a peptide where Cys284, 285, 287, 
288, 290 and 291 were modified (Table S2).  However, due to technical problems we were 
not able to generate enough material to produce reproducible data for the different 
acylated forms of full length STX19. Thus, we repeated the experiments with GFP-STX19275-
294. As before we identified C-terminal tryptic peptides (VLCCWCCPCCSSK) that showed 
evidence of S-acylation (Fig. 3G, H and Table S2). Several forms of the peptide were 
identified including, unmodified (6 alkylated Cys), 2 S-acylation sites (4 alkylated Cys), 3 S-
J
o
u
rn
a
l o
f 
C
e
ll 
S
c
ie
n
c
e
 
 A
c
c
e
p
te
d
 m
a
n
u
sc
ri
p
t
acylation sites (3 alkylated Cys), 4 S-acylation sites (2 alkylated Cys), 5 S-acylation sites (1 
alkylated Cys), 6 S-acylation sites (0 alkylated Cys) at a false discovery rate of 1% and a 
posterior error probability <0.01. Peptides containing residues predicted to be S-acylated 
were either exclusively identified in plus hydroxylamine treated samples or present in both 
plus and minus hydroxylamine treated samples but with at least a 5-fold increase in 
abundance after hydroxylamine treatment (Fig. 3G). The presence of a signal in the control 
(minus hydroxylamine treated samples) is likely arising from low-level loss of S-acylation 
during incubation steps (Jones et al., 2012). Cys284, 285, 287, 288, 290 and 291 all show 
evidence of S-acylation (false localisation rate of 1%) (Fig. 3G). However, no evidence of S-
acylation was observed for Cys280. The distribution of S-acylated forms of STX19 is striking 
in that the majority of STX19 is S-acylated at 5 or 6 cysteines and that the fractional 
occupancy of S-acylation (ratio of S-acylated/total intensity of the peptide VLCCWCCPCCSSK) 
is high; 87% of STX19 was modified with at least 4 acyl groups (Fig. 3G). These results 
indicate that the six most C-terminal cysteine residues of STX19 can be S-acylated.  
 
STX19 is stably associated with membranes 
S-acylation is the only lipid modification that is reversible and proteomic-based approaches 
have measured that up to 10% of the S-acyl-proteome is actively undergoing a cycle of S-
acylation and de-S-acylation (Martin et al., 2011). Thus, we wondered whether STX19 could 
also be cycling on and off membranes in a similar way to RAS or Ykt6 (Fukasawa et al., 2004; 
Lin and Conibear, 2015). To test this idea, we made use of a knock sideways approach, 
which is a protein re-targeting method (Robinson and Hirst, 2013). In this system, FKBP 
tagged peripheral proteins are re-routed on to mitochondria that are expressing an FRB 
domain construct in the presence of rapamycin. For example, FKBP-tagged AP2 adaptor 
complex is completely rerouted from the plasma membrane on to mitochondria within 10 
minutes of treatment with rapamycin (Robinson et al., 2010).  Thus, if STX19 is cycling on 
and off membranes we should be able to use this approach to re-direct it to mitochondria. 
HeLaM cells were transfected with FKBP-GFP (positive control), FKBP-myc-STX191-294 and 
two constructs, which cannot be S-acylated, FKBP-myc-STX191-277 and FKBP-myc-
STX19P1+P2+P3 (see Fig. 5 for fuller description of this construct) . The cells were then treated 
with or without rapamycin for 10 minutes at 37°C and fixed and stained for the indicated 
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constructs. As expected, FKBP-GFP was efficiently retargeted to mitochondria (Fig. 4A). 
However, S-acylated STX19 (FKBP-myc-STX191-294) remained associated with the plasma 
membrane (Fig. 4B), even after incubations of up to 1 hour (data not shown).  We also 
observed that in some cells it was the mitochondria that were rerouted to the plasma 
membrane, suggesting that STX19 cannot be easily removed from membranes (Fig. 4E). 
When we repeated these experiments with mutant forms of STX19 that cannot be S-
acylated (FKBP-myc-STX191-277 and FKBP-myc-STX19P1+P2+P3) we observed that these 
constructs were efficiently re-targeted to mitochondria (Fig. 4C and D). Taken together our 
results indicate that S-acylated STX19 is stably associated with membranes and is not rapidly 
cycling on and off membranes.   
 
Multiple acyl chains play a role in the correct targeting of STX19 to tubular recycling 
endosomes 
The mass spectrometry experiments identified that the six most C-terminal cysteine 
residues of STX19 can be S-acylated. These cysteines are organised into three pairs 
separated by a tryptophan and a proline residue respectively (Fig. 5A). To gain an insight 
into which of the cysteines pairs are most important for STX19 targeting we have replaced 
them with leucine residues that cannot be S-acylated.  We have generated a series of 
constructs where each cysteine pair (P), was mutated separately (P1, P2, and P3) or in 
combination (P1+2, P2+3, P1+3 and P1+2+3) (Fig. 5A). The cysteine pairs are numbered 
from the C-terminus so P1 is a construct where the most C-terminal cysteine pair has been 
mutated. HeLaM cells were transfected with either wild-type or mutant HA tagged STX19 
constructs and then analysed by immunofluorescence microscopy (Fig. 5B and quantified in 
C). When we mutated each cysteine pair separately no significant difference was observed 
between the localisation of the wild-type (HA-STX191-294) and mutant constructs (P1, P2 and 
P3) consistent with there being multiple sites of S-acylation as determined by mass 
spectrometry. However, when we mutated several cysteine pairs simultaneously (P1+2 and 
P1+3) we observed a significant effect on STX19 localisation. In these mutants, STX19 is still 
targeted to the plasma membrane but there is a significant reduction in the number of cells 
showing tubular staining (Fig. 5C). In contrast, the construct where the last cysteine pair was 
intact (P2+P3) showed significant tubular staining suggesting that this cysteine pair is most 
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important for targeting STX19 to tubular recycling endosomes. As would be expected, the 
construct where all of the cysteines had been mutated (P1+2+3) behaved in a similar way to 
a construct where the cysteine-rich domain was deleted (HA-STX191-277). In both cases, the 
constructs were completely cytosolic and were not targeted to tubular recycling 
endosomes. As observed earlier, perturbing S-acylation of STX19 caused the levels of some 
of the mutant proteins (P1+2, P2+3, P1+3 and P1+2+3) to be reduced (see Fig. 6A) so longer 
exposure times were needed to obtain some of the images. In summary, our data suggest 
that the last cysteine pair (P1) is the most critical for targeting STX19 to tubular recycling 
endosomes. However, other cysteine pairs can compensate for its loss.  
 
S-acylation regulates the stability of STX19 
From the immunolocalisation studies, it became apparent that interfering with the S-
acylation of STX19 perturbs its stability. To investigate this further, we transfected HeLaM 
cells with either wild-type (HA-STX191-294) or the mutant STX19 constructs (HA-STX19: P1, 
P2, P3, P1+2, P2+3, P1+3, P1+2+3, and HA-STX191-277) and performed immunoblotting using 
antibodies against HA and ɶ-adaptin as a loading control (Fig. 6A and quantified in B). As 
observed by microscopy, the levels of the mutant constructs, P1+2, P1+3, P1+2+3 and HA-
STX191-277 were significantly reduced compared to wild-type STX19. We hypothesised that 
the mutant constructs may be degraded by ubiquitination so we repeated the experiment in 
the presence of the proteasomal inhibitor MG132 (Lee and Goldberg, 1998). Addition of 
MG132 to the cells significantly increased the levels of the mutant constructs indicating that 
they are being ubiquitinated and targeted for proteasomal degradation. In support of this 
hypothesis, we and others have identified that STX19 is ubiquitinated on several lysine 
residues by mass spectrometry (Fig. S3) (Boeing et al., 2016). Increasing the levels of the 
mutant constructs using MG132 does not rescue their ability to target to the plasma 
membrane and/or tubular recycling endosomes indicating that S-acylation is essential for 
this process (Fig. S4).  
Our results suggest that when the cysteine-rich domain of STX19 is not S-acylated it 
becomes a novel degron. To test this hypothesis, we mutated all the cysteine pairs in a 
construct where the cysteine-rich domain is fused to the C-terminus of GFP (GFP-STX19275-
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294/P1+2+3). HeLaM cells were transfected with GFP, GFP-STX19275-294 or GFP-STX19275-294/P1+2+3 
and their levels determined by immunoblotting (Fig. 6C).  The levels of GFP-STX19275-
294/P1+2+3 were significantly reduced compared to that of the wild-type STX19 reporter. As 
predicted, the mutant protein is not targeted to the plasma membrane or tubular recycling 
endosomes (Fig. 6D). It is possible that the degradation phenotype is simply caused by the 
insertion of multiple leucines within the cysteine-rich domain and does not reflect a true 
physiological process. To exclude this possibility, we have used the drug 2-BP to block S-
acylation of the wild-type construct.  HeLaM cells were transfected with GFP-STX19275-294 
and treated with increasing concentrations of 2-BP overnight. The cells were then harvested 
and immunoblotting performed using antibodies against GFP and ɶ-adaptin (Fig. 6E and 
quantified in F). The levels of the reporter construct were dramatically reduced in a dose-
dependent manner suggesting that the cysteine-rich domain of STX19 is a degron that 
senses whether STX19 is S-acylated. Our immunoblotting results, from the truncated STX19 
construct (HA-STX191-277), also suggest that there must be an additional degron located 
upstream of the cysteine-rich domain, as the truncated protein is still degraded even when 
the cysteine-rich domain is removed. Our results indicate that S-acylation regulates both the 
stability and membrane targeting of STX19. 
 
zDHHCs 2, 3, 7, 11, and 12 are able to S-acylate STX19  
S-acylation in mammals is catalysed by 23 S-acyltransferases (Fukata et al., 2004). These 
enzymes are polytopic membrane proteins that have a conserved zDHHC motif and are 
localised to various membranes including the ER, Golgi, endosomes and plasma membrane 
(Ohno et al., 2006). To identify which zDHHC enzymes catalyse STX19 S-acylation, we have 
made use of an in vitro assay where S-acylation is measured based on the incorporation of 
17-octadecynoic acid (17-ODYA) (Martin and Cravatt, 2009; Yap et al., 2010). This label is 
reacted with the azide dye, IR-800 and the level of labelling quantified using an infrared 
imaging system. HEK-293T cells were co-transfected with GFP-STX191-294 and 23 different S-
acyltransferases and the amount of 17-ODYA labelling quantified by measuring the ratio of 
IR-800 signal to GFP signal (Fig. 7A and quantified C). The samples were also probed for HA 
to verify the expression of the HA-tagged zDHHCs (Fig. 7B).  In the control transfection 
(vector alone), there is a faint IR800 signal at the predicted molecular weight for GFP-
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STX191-294, indicating that the protein is being S-acylated by the endogenous S-
acyltransferases expressed in HEK-293T cells. This signal was significantly increased when 
zDHHCs 2, 3, 7, 11, 12 were co-transfected with STX19 suggesting that STX19 is a substrate 
for these enzymes (Fig. 7C). To determine if the cysteine-rich domain construct is also S-
acylated by the same enzymes, HEK-293T cells were co-transfected GFP-STX19275-294 and a 
subset of the zDHHC library (Fig. 7D and quantified in F). Like full length STX19, the 
cysteine-rich domain construct is also S-acylated by zDHHCs 2, 3, 7, 11, 12. In addition, 
zDHHC14 and 15 also significantly increased the IR-800 signal for this construct. These 
enzymes also increased the level of S-acylation of full length STX19 but the trend was not 
significant. To determine which of these enzymes most likely S-acylate STX19 in HeLaM cells 
we have examined their expression levels using microarray data (Fig. 7H) (Gordon et al., 
2010; Kozik et al., 2013). zDHHCs 3, 7, 11 and 12 are all expressed in HeLaM cells. However, 
zDHHCs 2 is expressed at very low levels suggesting it is unlikely to play a major role in S-
acylation in HeLaM cells. zDHHCs 3, 7, 11 and  12 are localised to the Golgi in mammalian 
cells (Ohno et al., 2006) suggesting that STX19 may be S-acylated at the Golgi and then 
traffic to the cell surface or tubular recycling endosomes. In support of this hypothesis we 
find that over-expression of zDHHC 3 or 7 significantly increase the Golgi localised pool of 
GFP-STX19275-294 (Fig. S5). 
 
Over-expressed GFP-STX19 perturbs Rab8 localisation 
The precise function of STX19 is still unclear. However, endogenous STX19 shows a high 
degree of co-localisation with Rab8. Thus, we hypothesised that STX19 might play a role in 
Rab8 trafficking. To test this hypothesis, we over-expressed GFP (control), GFP-STX191-294 or 
GFP-STX191-277, (which cannot be S-acylated) and examined the steady-state localisation of 
Rab8 (Fig. 8A and quantified in B). In cells expressing GFP, Rab8 was localised to a range of 
membranous compartments, including tubular recycling endosomes, the cleavage furrow 
and the plasma membrane (Peranen, 2011). In cells with low to moderate levels of GFP-
STX191-294 we found that Rab8 localisation was un-perturbed and that in many cells there 
was good co-localisation with GFP-STX191-294 (Fig. 2D). However, in cells with moderate to 
high expression levels of GFP-STX191-294 (1.5-fold mean intensity and above) we found Rab8 
to be targeted to membrane protrusions just at or under the plasma membrane (Fig. 8A). In 
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cells over-expressing GFP-STX191-277, (which cannot be S-acylated), we did not observe any 
change in Rab8 localisation, even in cells, which had very high expression levels (5-fold 
mean intensity and above). Our results suggest that STX19 may have a role in Rab8 
trafficking and that STX19 must be S-acylated to perturb this pathway.  
 
DISCUSSION 
STX19 is one of the least characterised Q-SNAREs in the human genome and there are only a 
handful of publications that have investigated its biology. Work from several labs including 
our own has identified that depleting STX19 using RNAi leads to defects in constitutive 
secretion (Gordon et al., 2010; Simpson et al., 2012) and endosome to TGN transport 
(Breusegem and Seaman, 2014). Biochemical studies from our group have identified that 
STX19 interacts with the R-SNAREs VAMPs 3 and 8 and the Qbc SNAREs SNAP23, 25 and 29 
supporting its role in membrane fusion at the plasma membrane.  In this study, we have set 
out to elucidate where STX19 is localised and determine how S-acylation regulates its 
trafficking and function.  
 
A pool of STX19 co-localises with Rab8 and MICAL-L1  
Our localisation data indicate that a pool of endogenous STX19 is localised to tubular 
recycling endosomes where it co-localises with Rab8 and MICAL-L1, proteins that have been 
shown to be involved in the endocytic recycling of proteins internalised by non-clathrin 
mediated endocytosis (Rahajeng et al., 2012; Sharma et al., 2009). In addition, Rab8 has also 
been shown to be a key player in cell polarity (Vidal-Quadras et al., 2017) and have an 
involvement in exocytosis (Grigoriev et al., 2011).  This is the first time that a SNARE has 
been localised to this compartment. Currently, it is unclear whether STX19 is: a) simply 
recycling through this compartment back to the cell surface, b) involved in the fusion of 
endocytic material with the plasma membrane; or c) required for the fusion of material with 
tubular recycling endosomes. Over-expression of GFP-STX19 causes Rab8 positive vesicles to 
accumulate in membrane protrusions just at or under the plasma membrane. Our 
interpretation of this result is that GFP-STX19 is acting in a dominant-negative manner and 
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is blocking the fusion of Rab8 positive vesicles with the plasma membrane. In the future, it 
will be interesting to more precisely define the role of STX19 in Rab8 trafficking and cell 
polarity.   
 
S-acylation regulates the levels of STX19  
Inhibiting STX19 S-acylation either by genetic or chemical means causes the protein to be 
degraded via the proteasome. Our experimental data suggest that STX19 contains at least 
two degrons. The first degron is formed when the cysteine-rich domain is not S-acylated and 
the second is located upstream of this region. The degron present in the de-S-acylated 
cysteine-rich domain can efficiently target stable proteins such as GFP for degradation.  At 
present, it is unclear what motifs or residues in STX19 are being recognised by the 
ubiquitination machinery. However, the cysteine-rich domain of STX19 contains several 
bulky hydrophobic residues (tryptophan and phenylalanine) that most likely would not 
normally be exposed to the cytoplasm when this region is S-acylated. Many S-acylated 
proteins also contain bulky hydrophobic residues in close proximity to the lipidated cysteine 
residues (Collins et al., 2017), suggesting that this could be a general mechanism by which 
de-S-acylated proteins are recognised for degradation. In the future, it will be of interest to 
determine if S-acylation is used as a mechanism to post-translationally regulate the levels of 
STX19.  
 
STX19 is most likely S-acylated at the Golgi and then traffics to the cell surface 
To identify the enzymes involved in S-acylating STX19, we performed a screen using over-
expressed zDHHCs. We found that full length STX19 and the C-terminal cysteine-rich domain 
of STX19 are good substrates for several zDHHCs (2, 3, 7, 11 and 12) and both proteins were 
predominantly S-acylated by the same enzymes. This data indicates that the protein 
sequence of the cysteine-rich domain contains all the necessary information required for 
substrate recognition and S-acylation. zDHHCs 3, and 7 have been shown to have a broad 
substrate specificity and S-acylate proteins including HRAS, SNAP25, SNAP23, and cysteine 
string protein (Greaves and Chamberlain, 2011a; Greaves et al., 2010; Greaves et al., 2008; 
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Lu et al., 2012). However, very few substrates have been identified for zDHHC 11. Based on 
our expression analysis, zDHHCs 3, 7, 11 and 12 are the enzymes most likely to be involved 
in S-acylating STX19 in HeLaM cells. Due to the significant level of redundancy observed 
between these enzymes (Ohno et al., 2012), we have not attempted to further define which 
enzymes S-acylate STX19. All of these zDHHCs are localised to the Golgi, suggesting that 
STX19 is first S-acylated at the Golgi and then traffics to the plasma membrane and/or 
tubular recycling endosomes.  
 
S-acylation targets STX19 and other peripheral proteins to tubular recycling endosomes 
One of the most striking observations in this study is that we have identified that S-acylation 
is a key determinant in targeting STX19 to tubular recycling endosomes and replacing the 
lipid anchor with a conventional transmembrane domain, from another Q-SNARE, 
significantly reduces the targeting of STX19 to this compartment. This data is consistent with 
S-acylation acting not merely as a membrane anchor but providing information that is 
critical for STX19 sorting. At present, it is unclear how S-acylation targets STX19 to tubular 
recycling endosomes. There are several possible mechanisms: 1) S-acylation targets STX19 
to lipid microdomains at the cell surface where it is subsequently internalised via non-
clathrin mediated endocytosis. 2) STX19 is directly recruited to this compartment from the 
cytosol through a cycle of S-acylation and de-S-acylation.  At present, we favour mechanism 
1 because: a) there is a significant body of literature indicating that S-acylated proteins are 
associated with lipid microdomains at the cell surface (Chamberlain et al., 2001; Melkonian 
et al., 1999; Salaun et al., 2004), b) STX19 is stably associated with membranes, and c) STX19 
is degraded when not S-acylated. We have observed that other S-acylated proteins (HRAS 
and S-acylated GFP) are also localised to tubular recycling endosomes suggesting that S-
acylation may be a key factor in targeting proteins to this compartment. In the future, it will 
be interesting to determine how general this mechanism is and what cellular machinery is 
involved in sorting S-acylated proteins to this compartment.  
In conclusion, we have elucidated that S-acylation is critical for targeting STX19 to tubular 
recycling endosomes and that this modification may have a broader role in sorting proteins 
to this compartment. In addition, STX19 may also prove useful for those elucidating the 
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mechanism of zDHHC substrate specificity, protein turnover and Rab8 dependent 
trafficking.  
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Figure 1. A pool of STX19 is localised to the plasma membrane and branched tubular 
membranes. A) HeLaM cells were seeded onto coverslips, transfected with either HA-STX19 
or STX19-HA and grown overnight. The cells were then fixed and stained with antibodies 
against HA. B) HeLaM cells were either mock transfected or transfected with siRNA targeting 
STX19 using a 96 hour double transfection protocol. The cells were seeded onto coverslips, 
fixed and stained with antibodies against STX19. C) HeLaM cells were seeded onto coverslips 
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and grown overnight. The cells were fixed and stained with antibodies against STX19 and 
MICAL-L1. HeLaM cells were seeded onto coverslips, transfected with Strawberry-Rab8 and 
grown overnight. The cells were then fixed and stained with antibodies against STX19. 
HeLaM cells were seeded onto coverslips and grown overnight. The next day the cells were 
incubated with antibodies against CD55 for 1 hour at 37°C. The cells were then fixed and 
stained with antibodies against STX19. Scale bar 10 µm. 
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Figure 2. The C-terminal cysteine-rich domain of STX19 is essential for targeting STX19 to 
tubular recycling endosomes. A) Diagrammatic representation of STX19 and the expression 
constructs used in this figure.  The position of the predicted Habc domain, SNARE motif, 
cysteine-rich domain (C) and transmembrane domain (TM) have been highlighted. A 
sequence alignment was performed using the cysteine-rich domain and a graphical 
representation of the sequence conservation generated by WebLogo 3 (Crooks et al., 2004; 
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Schneider and Stephens, 1990). The x-axis shows the position of each amino acid in the 
cysteine-rich domain and the height of the y-axis indicates the information content at each 
position (measured in bits). Amino acids are colour coded as follows; blue for charged, black 
for hydrophobic and green for polar. B) To determine which domains of STX19 are 
important for targeting STX19 to membranes, HeLaM cells were transfected with the 
indicated HA tagged expression constructs. The cells were then fixed and stained with 
antibodies against HA and Rab8 (the representative Rab8 images can be seen in Fig. S1).  C) 
The efficiency by which the STX19 constructs were targeted to this compartment were 
manually quantified by counting the number of cells that showed STX19 staining that co-
localised with Rab8. Between 50 and 100 cells were imaged for each construct. Error bars 
show the SEM for three independent experiments. The P values for each sample were 
calculated (** indicates P ч 0.01 and *** ч 0.001).  D) HeLaM cells were transfected with 
GFP-STX191-294 or GFP-STX19275-294, fixed and stained with antibodies against Rab8. Scale bar 
10 µm.  
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Figure 3. The cysteine-rich domain of STX19 is S-acylated on multiple cysteines and this 
modification is critical for targeting STX19 to the plasma membrane and tubular recycling 
endosomes.  
A-D) To determine if recombinant STX19 was S-acylated in vivo, HelaM cells were 
transfected with either GFP-STX191-294 or GFP-STX19275-294 and treated with 100 µM 2-BP for 
16 hours. The cells were then fixed and imaged. Scale bar 10 µm. To quantify the effect of 2-
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BP treatment on the STX19 expression constructs, between 50 and 100 cells were counted 
and the number of cells with cytoplasmic STX19 staining quantified. Error bars show the 
SEM from three independent experiments.  The P values for each sample were calculated 
(**** indicates P ч 0.0001). E and F) To determine if endogenous STX19 is S-acylated in vivo, 
HeLaM cells were grown on coverslips overnight and treated with 100 µM 2-BP for 16 hours. 
The cells were then fixed and stained with antibodies against STX19 and MICAL-L1. To 
quantify the effect of 2-BP on STX19 localisation, between 50 and 100 cells were counted 
and the number of cells with tubular STX19 staining quantified (as defined by overlap with 
MICAL-L1 positive tubules). Error bars show the SEM from three independent experiments.  
The P values for each sample were calculated (*** indicates P чч 0.001).  G) To identify 
which cysteine residues of STX19 are S-acylated, immuno-isolated GFP-STX19275-294 was 
reduced, alkylated and treated (+/- 1 M hydroxylamine) to cleave thioester bonds. The 
samples were then digested with trypsin and the resulting peptides quantified using mass 
spectrometry.  The hydroxylamine sensitivity of the cysteine residues was determined by 
measuring the relative intensity (extracted ion chromatogram) non-alkylated peptides in the 
presence or absence of hydroxylamine. H) Diagram showing the position and sequence of 
the tryptic peptide identified by mass spectrometry that shows evidence of S-acylation. The 
positions of the individual S-acylation sites are marked in dark blue.    
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Figure 4. STX19 is stably associated with membranes 
To determine if STX19 is cycling on and off membranes we have made use of the knock 
sideways approach.  HeLaM cells were co-transfected with MitoTRAP (Mito-mCherry-FRB) 
and either FKBP-GFP (positive control)(A), FKBP-myc-STX191-294 (B), FKBP-myc-STX191-277 (C) 
and FKBP-myc-STX19P1+P2+P3 (construct in which all the cysteines have been mutated to 
leucine)(D). 24 hours post-transfection the cells were then treated with or without 1 PM 
rapamycin for 10 minutes. The cells were then fixed and stained with antibodies against 
myc. Scale bar 10 µm. E) HeLaM cells were co-transfected with MitoTRAP (Mito-mCherry-
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FRB) and FKBP-myc-STX191-294. 24 hours post transfection the cells were then treated with 
or without 1 PM rapamycin for 10 minutes. The cells were then fixed and stained with 
antibodies against myc. Scale bar 20 µm. 
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Figure 5. Multiple cysteines are required for the correct targeting of STX19 to the plasma 
membrane and tubular recycling endosomes. A) The C-terminal sequence of the STX19 
expression constructs used in this figure are shown. The positions of the mutant residues 
are highlighted in red. The cysteine pairs were numbered from the C-terminus. B) HeLaM 
cells were grown overnight on coverslips and then transfected with the indicated STX19 
constructs. 24 hours post-transfection, the cells were fixed and stained for HA and Rab8. For 
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simplicity, only the HA staining is shown. Scale bar 10 µm. C) To quantify the effect of these 
mutations on STX19 membrane targeting, between 50 and 100 cells were counted for each 
construct and the percentage of cells showing STX19 staining on tubular recycling 
endosomes quantified (as defined by overlap with Rab8 positive tubules). Error bar shows 
SEM from three independent repeats.  The P values for each sample were calculated (*** 
indicates P ч 0.001).   
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Figure 6. S-acylation regulates the stability of STX19. A) HeLaM cells were grown overnight 
and transfected with the indicated HA-STX19 constructs. 8 hours post-transfection, the cells 
were treated with or without 5 µM MG132. 16 hours later the cells were harvested, cell 
lysates prepared, separated by SDS-PAGE and transferred onto membranes. The 
membranes were then probed for HA and ɶ-adaptin as a loading control. B) Western blots 
from three independent experiments were quantified.  Error bars show the SEM from three 
independent repeats. The P values for each sample were calculated (** indicates P ч 0.01 
and *** ч 0.001). C) HeLaM cells were transfected with either GFP, GFP-STX19275-294 or GFP-
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STX19275-294/P1+2+3. 24 hours post-transfection cell extracts were prepared from the cells, 
separated by SDS-PAGE and transferred onto PVDF membranes. The membranes were then 
probed for GFP and ɶ-adaptin as a loading control. D) HeLaM cells were grown on coverslips 
and transfected with GFP, GFP-STX19275-294 or GFP-STX19275-294/P1+2+3. 24 hours post-
transfection the cells were fixed and imaged. Scale bar 10 µm. E) HeLaM cells were 
transfected with GFP-STX19275-294. 8 hours post-transfection the cells were treated with the 
indicated concentrations of 2-BP. 16 hours later, cell extracts were prepared from the cells, 
separated by SDS-PAGE and transferred onto PVDF membranes. The membranes were then 
probed for GFP and ɶ-adaptin as a loading control. F) Western blots from three independent 
experiments were quantified. Error bars show the SEM from three independent 
experiments. The P values for each sample were calculated (* indicates P ч0.05; and *** ч 
0.001).   
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Figure 7. zDHHCs 2, 3, 7, 11 and 12 are capable of S-acylating STX19. HEK-293T cells were 
grown overnight and co-transfected with 23 HA-tagged S-acyltransferases and either GFP-
STX191-294 (A-C) or GFP-STX19275-294 (D-F). 24 hours post-transfection, the cells were labelled 
with 100 µM 17-octadecynoic acid (17-ODYA ) for 3 hours at 37°C. The cells were washed, 
lysed and incubated with the click reaction buffer containing azide IR800 dye for 1 hour. The 
samples were then acetone precipitated and resuspended in 1X Laemmli sample buffer. The 
samples were then separated by SDS-PAGE and transferred onto nitrocellulose membranes 
for blotting with antibodies against HA or GFP. A and D) Representative images showing the 
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expression levels of the GFP-STX19 constructs and the level of IR-800 labelling for each 
transfection. The third panel shows the merged image for both channels.  B and E) 
Representative images showing the expression levels of the HA tagged S-acyltransferases for 
each transfection.  C and F) The level of 17-ODYA incorporation was calculated and 
normalised to the vector control. Error bars show SEM and the data from six independent 
experiments were used. The P values for each sample were calculated (* indicates P < 0.05 
and  *** < 0.001).  G) Diagram representing the phylogenetic relationship of the mammalian 
S-acyltransferases.   H) To estimate the expression levels of the S-acyltransferases in HeLaM 
cells, previously published microarray data was re-analysed (Gordon et al., 2010; Kozik et al., 
2013). The dotted line indicates the minimum level of signal that represents significant gene 
expression. Error bars show the experimental range for six independent biological repeats. 
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Figure 8. Over-expression of S-acylated GFP-STX19 perturbs the localisation of Rab8.  
HeLaM cells were grown overnight and transfected with either GFP, GFP-STX191-294 or GFP-
STX191-277 (which lacks the cysteine rich domain). 24 hours post-transfection, the cells were 
fixed and stained for Rab8 (A). Scale bar 10 µm. To quantify the effect of the various 
constructs on Rab8 localisation, between 50 and 100 cells were counted. Error bars show 
the SEM from three independent experiments (B).  The P values for each sample were 
calculated (**** indicates P ч0.0001). 
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Fig.	 S1.	 The	 C-terminal	 cysteine-rich	 domain	 of	 STX19	 is	 required	 for	
targeting	STX19	to	tubular	recycling	endosomes.	HeLaM	cells	were	grown	on	
coverslips	 overnight	 and	 transfected	 with	 the	 indicated	 HA-STX19	 expression	
constructs.	The	cells	were	then	fixed	and	stained	with	antibodies	against	HA	and	
Rab8.	Arrowheads	indicate	the	position	of	Rab8	tubules.	Scale	bar	10	µm.	
: ?Ğůů^Đŝ ? ?ĚŽŝ ? ? ? ? ? ? ? ? ?ũĐƐ ? ? ? ? ? ? ? ?^ƵƉƉůĞŵĞŶƚĂƌǇŝŶĨŽƌŵĂƚŝŽŶ
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Fig.	 S2.	 Other	 S-acylated	 proteins	 are	 efficiently	 targeted	 to	 tubular	
recycling	endosomes.	HeLaM	cells	were	co-transfected	with	mCherry-STX19275-
294	 and	 GFP-HRAS	 or	 pCAG-mGFP	 (GFP	 fused	with	GAP43	S-acylation	 sequence).	
The	 cells	were	fixed	24	hours	post	 transfection	and	mounted	onto	 slides.	 Scale	
bar	10	µm.		
: ?Ğůů^Đŝ ? ?ĚŽŝ ? ? ? ? ? ? ? ? ?ũĐƐ ? ? ? ? ? ? ? ?^ƵƉƉůĞŵĞŶƚĂƌǇŝŶĨŽƌŵĂƚŝŽŶ
J
o
u
rn
a
l o
f 
C
e
ll 
S
c
ie
n
c
e
 
 S
u
p
p
le
m
e
n
ta
ry
 in
fo
rm
a
ti
o
n
Fig.	S3.	STX19	is	ubiquitinated	at	several	lysine	residues.	To	identify	which	
residues	 of	 STX19	 are	 ubiquitinated,	 HeLaM	 cells	 were	 transfected	 with	 GFP-
STX191-294	and	incubated	with	5	µM	MG132	for	8	hours.	The	cells	were	lysed	and	
STX19	 immunoisolated	using	GFP-TRAP	beads.	 STX19	was	 then	digested	using	
trypsin	and	the	resulting	peptides	analysed	using	LC-MS/MS.		A)	Representative	
fragmentation	 spectrum	 showing	 identification	 of	 K206	 as	 a	 site	 of	
ubiquitination.	B)	Diagram	showing	the	position	of	ubiquitinated	lysine	residues	
in	STX19	marked	in	red	(K13	PhosphoSitePlus	data	and	K206	our	experimental	
data).	 Residues	 shaded	 in	 light	 blue	 indicate	which	 peptides	were	 detected	 by	
MS	analysis	of	GFP-STX9	IPs.		
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Fig.	S4.	Proteasomal	inhibition	does	not	rescue	the	membrane	association	
of	 mutant	 STX19	 constructs.	 HeLaM	 cells	 were	 grown	 overnight	 and	
transfected	with	 the	 indicated	HA-STX19	constructs.	 8	hours	post-transfection,	
the	 cells	were	 treated	with	or	without	5	µM	MG132	 for	a	 further	8	hours.	The	
cells	were	 then	 fixed	and	stained	with	antibodies	against	HA.	Scale	bar	10	µm.	
The	same	exposure	times	were	used	for	the	cells	treated	with	or	without	MG132.	
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Fig	S5.	GFP-STX19275-294	can	be	S-acylated	at	 the	Golgi	by	zDHHCs	3	and	7.	
A) HeLaM	 cells	 were	 grown	 on	 coverslips	 overnight	 and	 co-transfected	 with
GFP-STX19275-294	and	 the	 indicated	 enzymes.	 The	 cells	were	 fixed	 6	 hours	 post	
transfection	and	then	stained	with	antibodies	against	HA	and	GFP.	In	the	control	
cells,	 GFP-STX19275-294	 is	 predominantly	 cytoplasmic	 while	 in	 the	 cells	 over	
expressing	zDHHCs	3	or	7	it	is	localised	to	the	Golgi.	 	B)	In	a	parallel	experiment,	
cells	transfected	with	zDHHCs	3	or	7	were	also	treated	with	100	µM	2-BP.	In	the	
2-BP	 treated	 cells	 the	 Golgi	 localisation	 is	 lost	 indicating	 that	 it	 is	 due	 to	
increased	S-acylation	of	GFP-STX19275-294.	Scale	bar	10	µm.		
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Species	 C-terminal	protein	sequence	
Homo	sapiens	 KYKKRNPCRVLCCWCCPCCSSK 
Mus	musculus	 KYKKRNPCRALCCCCCPRCGSK 
Canis	lupus	familiaris	 KYKKRNPCKVLCCWCCPCCSSK 
Equus	ferus	caballus	 KYKKRNPCRVLCCWCCPCCGSK 
Ornithorhynchus	anatinus	 RYKKRNPCRVLCCWCCSCCN 
Gallus	gallus	 RYRKRHPCKVICCWCCPCCK   
Ophiophagus	hannah	 KYRKKNPCKALCCWCCSCCK   
Danio	rerio	 RYKKNNPLRRLCCCCCPWFR   
Xenopus	tropicalis	 KYKRKNPCRALCCCCFPCCK   
Table	 S1.	 Representative	 protein	 sequences	 used	 to	 perform	 the	 sequence	
alignment	shown	in	Fig.	2.		
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Sequence Mass	adduct Modification	state Mass Proteins
Gene	
name
Charges PEP Score
Delta	
score
Intensity	GFP-
Stx19_Tail+HA
Intensity	
Stx19_Tail	-HA
Intensity	
Stx19_FL	+HA
Intensity	
Stx19_FL	-HA
VLCCWCCPCCSSK 6	X	Cys(+57	Da) Unmodified 1775.638 Q8N4C7|STX19_HUMANStx19 2 7.26E-17 183.72 169.95 2.E+06 NaN NaN 1.E+06
VLCCWCCPCCSSK 4	X	Cys(+57	Da) 2	Palmitoylation 1661.595 Q8N4C7|STX19_HUMANStx19 2 5.44E-05 123.79 116.26 1.E+06 NaN 4.E+05 NaN
VLCCWCCPCCSSK 3	X	Cys(+57	Da) 3	Palmitoylation 1604.574 Q8N4C7|STX19_HUMANStx19 2 0.031439 45.915 37.202 1.E+06 NaN NaN NaN
VLCCWCCPCCSSK 2	X	Cys(+57	Da) 4	Palmitoylation 1547.552 Q8N4C7|STX19_HUMANStx19 2 0.006237 73.499 64.178 5.E+06 6.E+05 NaN NaN
VLCCWCCPCCSSK 1	X	Cys(+57	Da) 5	Palmitoylation 1490.531 Q8N4C7|STX19_HUMANStx19 2 0.002799 75.566 70.953 7.E+06 1.E+06 2.E+05 NaN
VLCCWCCPCCSSK 0	X	Cys(+57	Da) 6	Palmitoylation 1433.509 Q8N4C7|STX19_HUMANStx19 2 0.00024 106.4 81.161 2.E+07 4.E+06 3.E+05 NaN
GFP-STX19	(275-294aa) GFP-STX19	(1-294aa)
Table	S2.	Mass	spectrometry	data	associated	with	S-acylation	site	identification	
in	 STX19.	 Peptide	 sequence	 information	 and	 identification	 scores	 (PEP)	 are	
provided	 for	 each	 S-acylated	 form.	 S-acylated	 residues	 are	 inferred	 by	
quantitative	analysis	of	the	relative	levels	of	non-alkylated	cysteine	residues	(i.e.	
protected	 from	 alkylation	 by	 S-acylation)	 +/-	 hydroxylamine	 treatment.	 Label	
free	 quantification	 of	 peptides	 +/-	 hydroxylamine	 treatment	 was	 performed	
using	MaxQuant	calculated	peptide	intensities	in	columns	L-M	for	the	STX19	tail	
construct	(GFP-STX19	(275-294aa))	and	in	columns	N-O	for	the	full	length	STX19	
construct	(GFP-STX19	(1-294aa)).	
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